Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: Paclitaxel in refractory ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Carcinoma, Papillary
  • Ovarian Neoplasms
  • Paclitaxel
  • Peritoneal Neoplasms

abstract

  • This experience supports the hypothesis that a more prolonged delivery of paclitaxel (ie, > six courses), a cell-cycle-specific cytotoxic agent with limited or no cumulative toxicity, may result in an improved therapeutic outcome in ovarian cancer. This concept will need to be tested in a randomized phase 3 clinical trial.

publication date

  • March 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8622026

Additional Document Info

start page

  • 796

end page

  • 9

volume

  • 14

number

  • 3